I

Immuneering Corp
NASDAQ:IMRX

Watchlist Manager
Immuneering Corp
NASDAQ:IMRX
Watchlist
Price: 2.1 USD -0.47% Market Closed
Market Cap: 62.3m USD
Have any thoughts about
Immuneering Corp?
Write Note

Immuneering Corp
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Immuneering Corp
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
I
Immuneering Corp
NASDAQ:IMRX
Accumulated Depreciation
-$728.3k
CAGR 3-Years
-94%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accumulated Depreciation
-$7.1B
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Immuneering Corp
Glance View

Market Cap
61.5m USD
Industry
Biotechnology

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. The company is headquartered in Cambridge, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-07-30. The firm is focused on improving patient outcomes by advancing a pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Its development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Its lead product candidate, IMM-1-104, is designed to be a selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. The firm's oncology programs target mutations of the RAS/RAF/MEK/ERK, (MAPK) and the PI3K/AKT/mTOR (mTOR), pathways. Its oncology programs include Dual-MEK: IMM-1-104, MEK-io, Trifecta-MEK, KRAS4B, RAS Induction, Covalent-MEK, and PI3K-alpha. The firm's neuroscience pipeline on Alzheimer's Disease (AD). Its neuroscience programs include IMM-ALL-01 and IMM-ALL-03.

IMRX Intrinsic Value
2.89 USD
Undervaluation 27%
Intrinsic Value
Price
I

See Also

What is Immuneering Corp's Accumulated Depreciation?
Accumulated Depreciation
-728.3k USD

Based on the financial report for Dec 31, 2023, Immuneering Corp's Accumulated Depreciation amounts to -728.3k USD.

What is Immuneering Corp's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 3Y
-94%

Over the last year, the Accumulated Depreciation growth was -82%. The average annual Accumulated Depreciation growth rates for Immuneering Corp have been -94% over the past three years .

Back to Top